Back to Authors

Ward, John Harris

A5103979688 | I223532165

Mayo Clinic

University of Utah

Citations 2

A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 11505-11505

10.1200/jco.2018.36.15_suppl.11505

Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 9512-9512

10.1200/jco.2018.36.15_suppl.9512